Autoimmune thyroid disease in systemic lupus erythematosus

D Pyne, D A Isenberg

Ann Rheum Dis 2002;61:70–72

CONCISE REPORT

Autoimmune thyroid disease in systemic lupus erythematosus

D Pyne, D A Isenberg

Background: The reported prevalence of autoimmune thyroid disease (3.9–24%) and antithyroid antibodies (11–51%) in SLE varies considerably. Early reports were mainly based on short term studies of small cohorts.

Objective: To report the prevalence of autoimmune thyroid disease and thyroid antibodies in 300 patients with SLE, followed up at our centre between 1978 and 2000, by a retrospective analysis of case notes.

Results: The prevalence (5.7%) of hypothyroidism in our cohort was higher than in the normal population (1%), while that of hyperthyroidism (1.7%) was not significantly different. Overall 42/300 (14%) of our cohort had thyroid antibodies, rising to 15/22 (68%) in the subgroup who also had thyroid disease (p<0.001). Both antimicrosomal and antithyroglobulin antibodies were detected. The antibodies were found in equally high frequency in the hyperthyroid subgroup (80% patients), whereas in the hypothyroid subgroup antimicrosomal antibodies were more frequent than antithyroglobulin antibodies (64% v 41%). There was no significant difference in the frequency with which antimicrosomal or antithyroglobulin antibodies were detected between the hyperthyroid and hypothyroid subgroups (p=0.2).

Conclusion: Our patients with SLE had a prevalence of hypothyroidism, but not hyperthyroidism, greater than that of the normal population. The presence of either condition was associated with a higher frequency of both antimicrosomal and antithyroglobulin antibodies.

Autoimmune thyroid disease, marked by the presence of antibodies directed against thyroid antigens, has been associated with a number of non-organ-specific rheumatological disorders. These associations include systemic lupus erythematosus (SLE), Sjögren’s syndrome, and giant cell arteritis. A number of studies have suggested that thyroid disease is more common in SLE than in the general population, but there is disagreement as to whether both hypothyroidism and hyperthyroidism are more common or whether this finding is restricted to hypothyroidism alone. Both antithyroglobulin and antimicrosomal antibodies have been found with greater frequency in SLE than in the general population, even in lupus patients who do not have clinical thyroid disease. It is still a subject of discussion as to whether SLE is an independent risk factor for these thyroid abnormalities or whether this is a coincidental finding because the group most at risk for SLE, young to middle aged women, is precisely the same group most at risk for autoimmune thyroid disease.

In the main, earlier studies reporting the prevalence of thyroid antibodies and clinical thyroid disease in patients with SLE were based on relatively small cohorts of patients. As a result the reported prevalence (3.9–24%) of both clinical thyroid disease in SLE and the frequency (11–51%) of antithyroid antibodies in SLE have varied widely depending on the study cited. Here we report the prevalence of both hyperthyroid and hypothyroid disease in a group of 300 patients with SLE with follow up periods of up to 22 years at a single centre. We also report the prevalence of antithyroid microsomal and antithyroglobulin antibodies in this cohort.

Patients and methods

Clinical records and laboratory data on patients with SLE have been maintained at the Middlesex Hospital since January 1978. All these patients satisfy the American Rheumatism Association’s revised criteria for SLE published in 1982. The overwhelming majority (>85%) of patients seen between January 1978 and July 2000 had thyroid serology performed at or shortly after the diagnosis of SLE and then intermittently every two to four years thereafter. A small number of patients with SLE had been looked after elsewhere before referral to our unit; in these cases thyroid serology was initially performed at the time of referral. Thyroid serology was performed by haemagglutination (Wellcome) before 1984, and by particle agglutination (Fujirebio) from 1984 onwards. Thyroid stimulating hormone (TSH) levels were measured by radioimmunoassay (NETRIA, normal range 0.5–5.0 mU/l) before 1985, by immunoradiometric assay (NETRIA, normal range 0.5–5.0 mU/l) from 1985 until June 1993, and by microparticle enhanced enzyme immunoassay (Abbot IMX, normal range 0.3–5.0 mU/l) from June 1993 onwards.

Clinical records of these patients were studied retrospectively. χ² Tests were used to analyse the association between the presence of thyroid antibodies and clinical thyroid disease. The χ² test was also used to compare the frequency of thyroid antibodies between the hyperthyroid and hypothyroid subgroups.

Results

Thyroid Disease

Of our 300 lupus patients, 22 (7%) had thyroid disease. There were 17 (5.7%) cases of hypothyroidism; eight were diagnosed before the onset of SLE, six after, and three simultaneously. There were five cases (1.7%) of hyperthyroidism, two diagnosed before the onset of SLE and three afterwards.

Serology

Of the 300 lupus patients, 42 (14%) had thyroid autoantibodies. Of the 22 patients with both SLE and thyroid disease, 15 (68%) had thyroid antibodies (table 1). In those who had thyroid disease diagnosed after the diagnosis of SLE, thyroid antibodies were present before the diagnosis of thyroid disease was made. Both antimicrosomal and antithyroglobulin antibodies were detected in the cohort, 11 patients (3.7%) with

Abbreviations: EUSA, enzyme linked immunosorbent assay; SLE, systemic lupus erythematosus; TSH, thyroid stimulating hormone
antimicrosomal antibodies only, three (1.0%) with antithyroglobulin antibodies only, and 25 (8.3%) with both (table 2). Antithyroid antibodies were not expressed differently in those whose thyroid disease was diagnosed before SLE onset.

Both the antibodies were found in equally high frequency in the hyperthyroid subgroup with four out of the five cases (80%) having both antibodies and one having neither. In the hypothyroid subgroup there was a trend towards a higher frequency of antimicrosomal antibodies than antithyroglobulin antibodies; seven patients had both antibodies, six had neither, and four had only antimicrosomal antibodies. There was no significant difference in the frequency with which the autoantibodies were detected between the hyperthyroid and hypothyroid subgroups (p>0.2, \( \chi^2 \)).

**DISCUSSION**

In our series of 300 patients with SLE the prevalence (5.7%) of hypothyroidism was much higher than that quoted for the normal background population (1%), while the prevalence (1.7%) of hyperthyroidism was not significantly different.

A number of studies have looked at the prevalence of thyroid disease in SLE (table 3). The largest of these studies looked at the prevalence of thyroid disease in 332 patients with SLE admitted to hospital in the United States during a five year period. The overall prevalence of thyroid disease was 7.5%—6.6% with hyperthyroidism and 0.9% with hypothyroidism—results similar to our study.

Of the three UK studies cited in the table, one reported the prevalence of hyperthyroidism in SLE as 24%. However, these patients were clinically euthyroid, although biochemically hypothyroid as defined by a raised TSH. This high figure is discordant with most other studies and may be a result of the small patient numbers and very sensitive enzyme linked immunosorbent assay (ELISA) assay used to measure TSH. When an immunometric technique was used to detect TSH, as in the study by Vianna et al., a much lower prevalence (6%) of hypothyroidism was found.

Although most studies have shown that the prevalence of hypothyroidism in SLE is greater than the 1% quoted for the general population, the issue of whether hyperthyroidism is more prevalent in lupus than in the background population is still debatable. The frequency of hypothyroidism in the normal population is approximately 1.9%, and some studies (table 3) have quoted higher rates in their lupus cohorts. However, the larger studies, including our own, suggest there is no increase in the prevalence of hyperthyroidism in patients with SLE.

The prevalence of thyroid autoantibodies in our study was 14%. This is lower than figures from most previous studies. Westman and Walport, Magaro et al., and Kausman and Isenberg reported prevalences of thyroid antibodies of 51%, 45%, and 21% respectively in their lupus patients. In agreement with other studies, we found a higher prevalence of thyroid antibodies in lupus patients with thyroid disease (68%). Both antithyroid and antimicrosomal antibodies were detected in our study. Overall, there was a trend towards antimicrosomal antibodies being found more frequently, owing to their greater prevalence in the hypothyroid subgroup. This trend has been observed in earlier studies (table 2). We did not however find a statistically significant difference in the frequency with which either antimicrosomal or antithyroglobulin antibodies were detected between the hyperthyroid and hypothyroid subgroups.

Of our 300 patients, 42 had thyroid antibodies but only 22 had thyroid disease. It is recognised that the number of patients with SLE who test positive for thyroid antibodies on a single occasion is greater than the number who have clinical thyroid disease. Isenberg et al. showed that the serological status of a significant minority of patients fluctuates and patients may become thyroid antibody negative with time. This subgroup is unlikely to develop clinical thyroid disease.

The main shortcoming of our study is the lack of an age and sex matched population for comparison. Because the group affected with lupus—predominantly young to middle aged women—is largely identical to the group who develop autoimmune thyroid disease, it may be argued that any association seen is purely coincidental. Two studies have suggested that there is no statistically significant difference in the

### Table 1

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Number of lupus patients</th>
<th>Number with anti-MIC Ab</th>
<th>Number with anti-TGB Ab</th>
<th>Number with both antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>300</td>
<td>36</td>
<td>28</td>
<td>25</td>
</tr>
<tr>
<td>2</td>
<td>100</td>
<td>4</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>200</td>
<td>12</td>
<td>10</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>300</td>
<td>36</td>
<td>28</td>
<td>25</td>
</tr>
<tr>
<td>5</td>
<td>100</td>
<td>4</td>
<td>7</td>
<td>1</td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Number of lupus patients</th>
<th>Number with antimicrosomal antibodies only</th>
<th>Number with antithyroglobulin antibodies only</th>
<th>Number with both antibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>This study</td>
<td>300</td>
<td>5</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>1</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>4</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>5</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>6</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>7</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>8</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>9</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>10</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>11</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>12</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>13</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>14</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>15</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>16</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>17</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
<tr>
<td>18</td>
<td>100</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>19</td>
<td>200</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>20</td>
<td>300</td>
<td>36</td>
<td>36</td>
<td>36</td>
</tr>
</tbody>
</table>
prevalence of thyroid disease in SLE compared with age and sex matched controls,¹⁶ despite a higher prevalence of antithyroglobulin antibodies being found in the SLE group.¹⁶ Because only a few studies have examined this issue, and numbers were small, the question as to whether lupus patients have an excess of thyroid disease over and above that of age and sex matched controls remains debatable.

Despite this, our study indicates that a percentage (7%) of patients with SLE will develop thyroid disease and that the prevalence of hypothyroidism, but not hyperthyroidism, is greater than the overall prevalence in the background population. Furthermore, the presence of either condition in SLE is associated with a high prevalence of both antithyroglobulin and antimicrosomal antibodies. We would thus recommend the intermittent biochemical screening of thyroid function in patients with SLE, particularly if they are known to have thyroid antibodies, to identify clinical/subclinical thyroid disease.

Authors’ affiliations
D Pyne, D A Isenberg Centre for Rheumatology, University College London, Arthur Stanley House, 4th Floor, 40–50 Tottenham Street, London W1P 9PJ, UK
Correspondence to: Dr Pyne
Accepted 30 May 2001

REFERENCES
5 Boey ML, Fong PH, Lee JSC, Ng WY, Thao AC. Autoimmune thyroid disease in SLE in Singapore. Lupus 1993;2:51–4.
Autoimmune thyroid disease in systemic lupus erythematosus

D Pyne and D A Isenberg

Ann Rheum Dis 2002 61: 70-72
doi: 10.1136/ard.61.1.70

Updated information and services can be found at:
http://ard.bmj.com/content/61/1/70

References

This article cites 20 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/61/1/70#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Immunology (including allergy) (5144)
Systemic lupus erythematosus (571)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/